VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 212,702 shares, a drop of 61.3% from the February 12th total of 549,047 shares. Based on an average daily trading volume, of 435,988 shares, the short-interest ratio is currently 0.5 days. Currently, 0.7% of the shares of the stock are short sold. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 435,988 shares, the short-interest ratio is currently 0.5 days.

VYNE Therapeutics Stock Up 2.0%

Shares of VYNE opened at $0.60 on Wednesday. The company has a market cap of $20.05 million, a PE ratio of -0.77 and a beta of 2.00. The business has a fifty day moving average of $0.58 and a 200 day moving average of $0.45. VYNE Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.05.

Analysts Set New Price Targets

VYNE has been the topic of several recent research reports. Wall Street Zen upgraded shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $4.50.

Institutional Investors Weigh In On VYNE Therapeutics

Institutional investors have recently made changes to their positions in the company. Velan Capital Investment Management LP purchased a new stake in VYNE Therapeutics in the 2nd quarter worth about $50,000. Patient Square Capital LP boosted its position in shares of VYNE Therapeutics by 23.3% during the second quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock valued at $523,000 after buying an additional 60,000 shares during the period. XTX Topco Ltd bought a new position in shares of VYNE Therapeutics during the fourth quarter valued at approximately $46,000. Geode Capital Management LLC grew its stake in shares of VYNE Therapeutics by 64.2% during the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after buying an additional 88,030 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in shares of VYNE Therapeutics in the second quarter worth approximately $176,000. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.